Bio-Rad Launches High Performance Food Safety Solution for Powdered Infant Formula and Related Dairy Ingredients

Date: 
07/05/2020
The PIF Supplement
The PIF Supplement helps grow a variety of pathogens in a single enrichment broth.

Easy-to-use supplement enriches both Salmonella spp. and Cronobacter spp. in a single broth

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its PIF Supplement for the enrichment of Enterobacteriaceae, in particular Salmonella spp. and Cronobacter spp., in powdered infant formula — with or without probiotics — dairy ingredients, and cereal. It can also be used in testing environmental samples from production areas. The PIF Supplement was developed to be paired with Bio-Rad’s iQ-Check Real-Time PCR Test Kits and RAPID'Chromogenic Media to yield a highly performant method.

The Bio-Rad PIF Supplement meets the growing demand from dairy producers, such as infant formula manufacturers and service labs, to test for Salmonella and Cronobacter in large sample sizes. It provides unrivaled performance and meets the strict quality requirements of the industry in a cost-effective manner. To optimize recovery of the pathogens, the supplement inhibits background flora, such as lactic acid bacteria, bifidobacteria, and other gram-positive bacteria.

Using the PIF Supplement, users can enrich Salmonella and Cronobacter simultaneously from a single enrichment broth for samples up to 375 grams. After the enrichment step, any of the existing iQ-Check Real-Time PCR and RAPID'Chromogenic Media methods may be used to screen for these pathogens.

The PIF Supplement demonstrated excellent performance during the NF VALIDATION extension of the iQ-Check Cronobacter Real-Time PCR Detection Kit. The protocol was also included in the validation renewal of RAPID’Sakazakii Chromogenic Media.

Visit bio-rad.com/PIF to learn more about the PIF Supplement.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. IQ-CHECK is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
520-741-5653
wendy_lauer@bio-rad.com

CG Life
Alyssa Salela
630-935-6369
asalela@cglife.com